A new series of half-sandwich ruthenium(II) compounds [(η6-arene)Ru(L)Cl][CF3SO3] bearing 1,2,3-triazole
ligands (arene = p-cymene, L = L1 (1); arene = p-cymene, L = L2 (2); arene = benzene, L = L1 (3); arene = benzene, L2 (4); L1 = 2-[1-(p-tolyl)-1H-1,2,3-triazol-4-yl]pyridine
and L2 = 1,1′-di-p-tolyl-1H,1′H-4,4′-bi(1,2,3-triazole)
have been synthesized and fully characterized by 1H and 13C NMR and IR spectroscopy, mass spectrometry, and elemental
analysis. The molecular structures of 1, 2, and 4 have been determined by single-crystal X-ray
diffraction. The cytotoxic activity of 1–4 was evaluated using the MTS assay against human tumor cells,
namely ovarian carcinoma (A2780), colorectal carcinoma (HCT116), and
colorectal carcinoma resistant to doxorubicin (HCT116dox), and against
normal primary fibroblasts. Whereas compounds 2 and 4 showed no cytotoxic activity toward tumor cell lines, compounds 1 and 3 were active in A2780, while showing no
antiproliferative effect in human normal dermal fibroblasts at the
IC50 concentrations of the A2780 cell line. Exposure of
ovarian carcinoma cells to IC50 concentrations of compound 1 or 3 led to an accumulation of reactive oxygen
species and an increase of apoptotic and autophagic cells. While compound 3 displayed low levels of angiogenesis induction, compound 1 showed an ability to induce cell cycle delay and to interfere
with cell migration. When the in vivo toxicity studies
using zebrafish and chicken embryos are considered, compounds 1 and 3, which were not lethal, are promising
candidates as anticancer agents against ovarian cancer due to their
good cytotoxic activity in tumor cells and their low toxicity both in vitro and in vivo.